Section 1: Identification

Product name: Triclabendazole / Abamectin Formulation

Manufacturer or supplier's details
Company: MSD
Address: 33 Whakatiki Street - Private Bag 908
Upper Hutt - New Zealand
Telephone: +1-908-740-4000
Emergency telephone number: +1-908-423-6000
E-mail address: EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use: Veterinary product

Section 2: Hazard identification

GHS Classification
Specific target organ toxicity - repeated exposure (Oral): Category 2 (Liver, Blood)

GHS label elements
Hazard pictograms: 
Signal word: Warning
Hazard statements: H373 May cause damage to organs (Liver, Blood) through prolonged or repeated exposure if swallowed.
Precautionary statements:
Prevention:
P260 Do not breathe mist or vapours.
Response:
P314 Get medical advice/attention if you feel unwell.
Disposal:
P501 Dispose of contents/container to an approved waste disposal plant.

Other hazards which do not result in classification
None known.

Section 3: Composition/information on ingredients
SAFETY DATA SHEET

Triclabendazole / Abamectin Formulation

Version: 2.1  Revision Date: 10.12.2020  SDS Number: 5341823-00003  Date of last issue: 09.10.2020  Date of first issue: 05.12.2019

Substance / Mixture: Mixture

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Triclabendazole</td>
<td>68786-66-3</td>
<td>&gt;= 10 - &lt; 30</td>
</tr>
<tr>
<td>Abamectin (combination of avermectin B1a and avermectin B1b)</td>
<td>71751-41-2</td>
<td>&lt; 0.5</td>
</tr>
</tbody>
</table>

Section 4: First-aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention if symptoms occur.

In case of skin contact: Wash with water and soap as a precaution. Get medical attention if symptoms occur.

In case of eye contact: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: May cause damage to organs through prolonged or repeated exposure if swallowed.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Suitable extinguishing media: Water spray
                          Alcohol-resistant foam
                          Carbon dioxide (CO2)
                          Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during firefighting: Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
                              Nitrogen oxides (NOx)
                              Metal oxides

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
                              Use water spray to cool unopened containers.
                              Remove undamaged containers from fire area if it is safe to do so.
                              Evacuate area.

Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
Section 6: Accidental release measures

Personal precautions, protective equipment and emergency procedures: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up: Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling: Do not breathe mist or vapours. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage: Keep in properly labelled containers.
Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types:

- Strong oxidizing agents

Section 8: Exposure controls/personal protection

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Triclabendazole</td>
<td>68786-66-3</td>
<td>TWA</td>
<td>30 μg/m3 (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td>Further information: DSEN</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wipe limit</td>
<td>100 µg/100 cm²</td>
<td></td>
<td>Internal</td>
<td></td>
</tr>
<tr>
<td>Abamectin (combination of avermectin B1a and avermectin B1b)</td>
<td>71751-41-2</td>
<td>TWA</td>
<td>30 µg/m3 (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td>Wipe limit</td>
<td>300 µg/100 cm²</td>
<td></td>
<td>Internal</td>
<td></td>
</tr>
</tbody>
</table>

Engineering measures: Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., dripless quick connections). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

- Filter type: Particulates type

Hand protection: Chemical-resistant gloves

Material: Consider double gloving.

Eye protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Section 9: Physical and chemical properties

- **Appearance**: suspension
- **Colour**: white
- **Odour**: No data available
- **Odour Threshold**: No data available
- **pH**: 5.0 - 7.0
- **Melting point/freezing point**: < 5 °C
- **Initial boiling point and boiling range**: No data available
- **Flash point**: No data available
- **Evaporation rate**: No data available
- **Flammability (solid, gas)**: Not applicable
- **Flammability (liquids)**: No data available
- **Upper explosion limit / Upper flammability limit**: No data available
- **Lower explosion limit / Lower flammability limit**: No data available
- **Vapour pressure**: No data available
- **Relative vapour density**: No data available
- **Relative density**: No data available
- **Density**: 1,050 - 1,080 g/cm³ (20 °C)
- **Solubility(ies)**
  - **Water solubility**: soluble
- **Partition coefficient: n-octanol/water**: Not applicable
- **Auto-ignition temperature**: No data available
- **Decomposition temperature**: No data available
- **Viscosity**
  - **Viscosity, kinematic**: No data available
- **Explosive properties**: Not explosive
- **Oxidizing properties**: The substance or mixture is not classified as oxidizing.
Section 10: Stability and reactivity

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions: Can react with strong oxidizing agents.
Conditions to avoid: None known.
Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

Section 11: Toxicological information

Exposure routes: Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity:
Not classified based on available information.

Components:
Triclabendazole:
Acute oral toxicity: LD50 (Mouse): > 8,000 mg/kg
LD50 (Rabbit): 206 mg/kg

Acute inhalation toxicity: LC50 (Rat): > 0.5 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity

Acute dermal toxicity: LD50 (Rat): > 4,000 mg/kg

Abamectin (combination of avermectin B1a and avermectin B1b):
Acute oral toxicity: LD50 (Rat): 24 mg/kg
LD50 (Mouse): 10 mg/kg
LDLo (Monkey): 24 mg/kg
Symptoms: Dilatation of the pupil

Acute inhalation toxicity: LC50 (Rat): 0.023 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity: LD50 (Rat): 330 mg/kg
LD50 (Rabbit): 2,000 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:
Triclabendazole:
Species: Rabbit
Result: Mild skin irritation

Abamectin (combination of avermectin B1a and avermectin B1b):
Species: Rabbit
Result: No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:
Triclabendazole:
Species: Rabbit
Result: No eye irritation

Abamectin (combination of avermectin B1a and avermectin B1b):
Species: Rabbit
Result: Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:
Triclabendazole:
Result: Not a skin sensitiser.

Abamectin (combination of avermectin B1a and avermectin B1b):
Test Type: Maximisation Test
Exposure routes: Skin contact
Result: Not a skin sensitiser.

Chronic toxicity

Germ cell mutagenicity
Not classified based on available information.
**Components:**

### Triclabendazole:

<table>
<thead>
<tr>
<th>Genotoxicity in vitro</th>
<th>Test Type: Bacterial reverse mutation assay (AMES)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Result: negative</td>
</tr>
</tbody>
</table>

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Result: negative

### Abamectin (combination of avermectin B1a and avermectin B1b):

<table>
<thead>
<tr>
<th>Genotoxicity in vitro</th>
<th>Test Type: Bacterial reverse mutation assay (AMES)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Result: negative</td>
</tr>
</tbody>
</table>

Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster lung cells
Result: negative

Test Type: Alkaline elution assay
Result: negative

| Genotoxicity in vivo | Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) |
|----------------------|-------------------------------------------------------------------------------------------------
|                      | Species: Mouse                                                                                  |
|                      | Application Route: Intraperitoneal injection                                                    |
|                      | Result: negative                                                                                  |

### Carcinogenicity

Not classified based on available information.

**Components:**

### Triclabendazole:

<table>
<thead>
<tr>
<th>Species</th>
<th>Mouse</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>2 Years</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
</tbody>
</table>

### Abamectin (combination of avermectin B1a and avermectin B1b):

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>105 weeks</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Mouse</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>93 weeks</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
</tbody>
</table>
**Reproductive toxicity**

Not classified based on available information.

**Components:**

**Triclabendazole:**

**Effects on fertility**

<table>
<thead>
<tr>
<th>Application Route</th>
<th>Test Type</th>
<th>NOAEL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>Fertility/early embryonic development</td>
<td>50 mg/kg body weight</td>
</tr>
<tr>
<td></td>
<td>Fertility</td>
<td>NOAEL</td>
</tr>
<tr>
<td></td>
<td>NOAEL</td>
<td>50 mg/kg body weight</td>
</tr>
</tbody>
</table>

**Effects on foetal development**

<table>
<thead>
<tr>
<th>Application Route</th>
<th>Test Type</th>
<th>NOAEL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>Embryo-foetal development</td>
<td>5.5 mg/kg body weight</td>
</tr>
</tbody>
</table>

**Abamectin (combination of avermectin B1a and avermectin B1b):**

**Effects on fertility**

<table>
<thead>
<tr>
<th>Application Route</th>
<th>Test Type</th>
<th>NOAEL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>Fertility</td>
<td>50 mg/kg body weight</td>
</tr>
<tr>
<td></td>
<td>NOAEL</td>
<td>50 mg/kg body weight</td>
</tr>
</tbody>
</table>

**Remarks:**

Maternal toxicity observed.
Application Route: Oral
Early Embryonic Development: NOAEL: 0.12 mg/kg body weight
Result: Fetotoxicity

Effects on foetal development:
Species: Mouse
Application Route: Oral
General Toxicity Maternal: NOAEL: 0.05 mg/kg body weight
Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
Result: Cleft palate
Remarks: Adverse developmental effects were observed

Species: Rabbit
Application Route: Oral
Developmental Toxicity: LOAEL: 2 mg/kg body weight
Result: Cleft palate, Teratogenic effects, Reduced embryonic survival
Remarks: Adverse developmental effects were observed

Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 1.6 mg/kg body weight
Result: Teratogenic effects

Reproductive toxicity - Assessment:
Some evidence of adverse effects on sexual function and fertility, based on animal experiments. Some evidence of adverse effects on development, based on animal experiments.

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
May cause damage to organs (Liver, Blood) through prolonged or repeated exposure if swallowed.

Components:
Triclabendazole:
Target Organs: Liver, Blood
Assessment: May cause damage to organs through prolonged or repeated exposure.

Abamectin (combination of avermectin B1a and avermectin B1b):
Exposure routes: Ingestion
Target Organs: Central nervous system
Assessment: Causes damage to organs through prolonged or repeated exposure.
Repeated dose toxicity

**Components:**

**Triclabendazole:**
- **Species**: Rat
- **NOAEL**: 6.6 mg/kg
- **LOAEL**: 69 mg/kg
- **Application Route**: Oral
- **Exposure time**: 13 Weeks
- **Target Organs**: Blood

- **Species**: Dog
- **NOAEL**: 3.4 mg/kg
- **LOAEL**: 37 mg/kg
- **Application Route**: Oral
- **Exposure time**: 13 Weeks
- **Target Organs**: Liver, Blood

- **Species**: Mouse
- **NOAEL**: 29 mg/kg
- **Application Route**: Oral
- **Exposure time**: 24 Months
- **Target Organs**: Liver

- **Species**: Rat
- **NOAEL**: 4 mg/kg
- **Application Route**: Oral
- **Exposure time**: 24 Months
- **Remarks**: No significant adverse effects were reported

**Abamectin (combination of avermectin B1a and avermectin B1b):**
- **Species**: Rat
- **NOAEL**: 1.5 mg/kg
- **Application Route**: Oral
- **Exposure time**: 24 Months
- **Target Organs**: Central nervous system
- **Symptoms**: Tremors, ataxia

- **Species**: Mouse
- **NOAEL**: 4.0 mg/kg
- **Application Route**: Oral
- **Exposure time**: 24 Months
- **Target Organs**: Central nervous system
- **Symptoms**: Tremors, ataxia

- **Species**: Dog
- **NOAEL**: 0.25 mg/kg
- **LOAEL**: 0.5 mg/kg
- **Application Route**: Oral
- **Exposure time**: 53 Weeks
- **Target Organs**: Central nervous system
- **Symptoms**: Tremors, weight loss
- **Remarks**: mortality observed
Species: Monkey
NOAEL: 1.0 mg/kg
Application Route: Oral
Exposure time: 14 Weeks
Target Organs: Central nervous system

**Aspiration toxicity**
Not classified based on available information.

**Experience with human exposure**

**Components:**

**Triclabendazole:**
Ingestion: Symptoms: Abdominal pain, Sweating, Headache, Nausea, Vomiting, anorexia, Dizziness, Fatigue, Cough, Fever, pruritis

**Abamectin (combination of avermectin B1a and avermectin B1b):**
Ingestion: Symptoms: May cause, Tremors, Diarrhoea, central nervous system effects, Salivation, tearing

---

**Section 12: Ecological information**

**Ecotoxicity**

**Components:**

**Abamectin (combination of avermectin B1a and avermectin B1b):**

**Toxicity to fish (Chronic toxicity):**
NOEC (Pimephales promelas (fathead minnow)): 0.52 µg/l
Exposure time: 32 d

**Toxicity to algae/aquatic plants:**
EC50 (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
Exposure time: 72 h

**Toxicity to daphnia and other aquatic invertebrates:**
EC50 (Daphnia magna (Water flea)): 0.34 µg/l
Exposure time: 48 h

**Toxicity to fish:**
LC50 (Oncorhynchus mykiss (rainbow trout)): 3.2 µg/l
Exposure time: 96 h

**Toxicity to fish:**
LC50 (Lepomis macrochirus (Bluegill sunfish)): 9.6 µg/l
Exposure time: 96 h

**Toxicity to fish:**
LC50 (Ictalurus punctatus (channel catfish)): 24 µg/l
Exposure time: 96 h

**Toxicity to fish:**
LC50 (Cyprinus carpio (Carp)): 42 µg/l
Exposure time: 96 h

**Toxicity to fish:**
LC50 (Cyprinodon variegatus (sheepshead minnow)): 15 µg/l
Exposure time: 96 h

**Toxicity to fish:**
EC50 (Americamysis): 0.022 µg/l
Exposure time: 96 h

**Toxicity to fish:**
EC50 (Daphnia magna (Water flea)): 0.34 µg/l
Exposure time: 48 h

**Toxicity to fish:**
EC50 (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
Exposure time: 72 h

---
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
- NOEC (Daphnia magna (Water flea)): 0.03 µg/l
  Exposure time: 21 d
- NOEC (Mysidopsis bahia (opossum shrimp)): 0.0035 µg/l
  Exposure time: 28 d

Toxicity to microorganisms:
- EC50: > 1,000 mg/l
  Exposure time: 3 h
  Test Type: Respiration inhibition

Persistence and degradability

Components:
Abamectin (combination of avermectin B1a and avermectin B1b):
- Stability in water: Hydrolysis: 50 %(< 12 h)

Bioaccumulative potential

Components:
Abamectin (combination of avermectin B1a and avermectin B1b):
- Bioaccumulation: Bioconcentration factor (BCF): 52
- Partition coefficient: n-octanol/water: log Pow: 4

Mobility in soil

Components:
Abamectin (combination of avermectin B1a and avermectin B1b):
- Distribution among environmental compartments: log Koc: > 3.6

Other adverse effects
No data available

Section 13: Disposal considerations

Disposal methods
- Waste from residues: Dispose of in accordance with local regulations.
- Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
  If not otherwise specified: Dispose of as unused product.

Section 14: Transport information

International Regulations

UNRTDG
- UN number: UN 3082
- Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
SAFETY DATA SHEET

Triclabendazole / Abamectin Formulation

Class : 9
Packing group : III
Labels : 9

IATA-DGR
UN/ID No. : UN 3082
Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.
(Abamectin (combination of avermectin B1a and avermectin B1b))

Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 964
Packing instruction (passenger aircraft) : 964
Environmentally hazardous : yes

IMDG-Code
UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(Abamectin (combination of avermectin B1a and avermectin B1b))

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

National Regulations

NZS 5433
UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(Abamectin (combination of avermectin B1a and avermectin B1b))

Class : 9
Packing group : III
Labels : 9
Hazchem Code : 3Z

Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.
Section 15: Regulatory information

Safety, health and environmental regulations/legislation specific for the substance or mixture

**HSNO Approval Number**

HSR100759 Veterinary Medicines Non dispersive Open System Application Group Standard 2017

**HSW Controls**

Certified handler certificate not required.
Tracking hazardous substance not required.
Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:

- **AICS**: not determined
- **DSL**: not determined
- **IECSC**: not determined

Section 16: Other information

**Further information**


Date format: dd.mm.yyyy

Full text of other abbreviations:

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect
SAFETY DATA SHEET

Triclabendazole / Abamectin Formulation

Version 2.1 Revision Date: 10.12.2020 SDS Number: 5341823-00003 Date of last issue: 09.10.2020
Date of first issue: 05.12.2019

Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

NZ / EN